MTOR and neoplasm with perivascular epithelioid cell differentiation: When comparing different systemic therapies, we found no difference in OS between patients treated with first-line chemotherapy versus those that received mTOR inhibitors, and the same was true for first-line cPFS, both in the cohort as a whole and in patients with malignant PEComa only.